Skip to content

Conjuran®(Polynucleotide) for knee Osteoarthritis

A Retrospective Pilot Study To Evaluate the Efficacy and Safety of Conjuran®(Polynucleotide) Compared to Hyruan Plus®(Sodium hyaluronate), Synovian®(BDDE cross-linked sodium hyaluronate) in Patients with Knee Osteoarthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005555
Enrollment
15
Registered
2020-10-29
Start date
2020-08-17
Completion date
Unknown
Last updated
2020-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) adult over 40 years old 2) Knee osteoarthritis patients of Grade l-lll according to Kellgren-Lawrence grading scale 3) 100mm VAS(visual analogue score) for pain during weight bearing more than 40mm in at least one joint of the bilateral knee joint

Exclusion criteria

Exclusion criteria: 1) patient with severe trauma or fracture history of the indicator knee joint 2) Those with rheumatoid arthritis or other metabolid arthritis 3) Patient with infection around the indicator knee joint 4) Those who have joint replacement surgery in the indicator knee joint 5) Those who have hip joint osteoarthritis in ipsilateral side of the indicator knee joint 6) Patient with other disease that may affect the safety and effectiveness evaluation of the indicator knee joint (e.g., patients with severe pain, such as complex pain regional syndrome, Paget's disease, intervertebral disc prolapse, and gout, recurrent pseudogout) 7) patient who received intra-articular hyaluronic acid injection within the previous three months of baseline(before study) or those who received intra-articular steroid injections within one month 8) those who received anticoagulant or platelet aggregation inhibitors within one week prior to the baseline (before study) 9) patient who received physiotherapy in the baseline (before study) within two weeks prior to the indicator knee joint

Design outcomes

Primary

MeasureTime frame
Visual analogue score (VAS);Korean version of Western Ontario and McMaster Universities(K-WOMAC);European quality of like-5 demension(EQ-5D);PainDETECT

Secondary

MeasureTime frame
Safety assessment

Countries

Korea, Republic of

Contacts

Public Contactjiyeong kim

The Catholic University of Korea, Seoul St. Mary's Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026